One Company with Diversified Quality. Agro Businesses with High Growth,
High Margins, Niche Markets & Innovative Technologies

 

Sino Agro Food, Inc. (SIAF) is an agricultural business focused on developing, producing and distributing high margin agricultural products in the People's Republic of China.

In P.R.C. the rapid progress of industrialization of the last decade has unbalanced the needs of developments and activities of the agriculture industry, (i.e. diminishing of agriculture land, scarcity of farm laborers, industrial pollution and the generally over usage of chemical etc.). Therefore the P.R.C. Government has in recent years directed many incentive schemes and policies with the aim to revitalize and to modernize its agriculture industry. (i.e. Protection of agriculture land, stringent laws in governing the ownership and usage of agriculture land, tax free incentive applying to incomes generated from the industry and enforcing environmental friendly developments etc.) Management of the Company has many years of practical and professional experience in various and many sectors of the agriculture industry and decided in year 2004 that it was the right timing and there would be many opportunities available to develop agricultural ventures in P.R.C.

The Company intends to focus on meeting the increasing demand of China's rising middle class for gourmet and high quality food. Current lines of business include fisheries, dairies, and agricultural production of capers and sod with the direct association of modern fishery and cultivation technologies:

Company Web Site: http://www.siafchina.com/

Company Financial Summary

Company financial information available on pinksheets.com. Numbers are un-audited and may change slightly, company currently undergoing audit for previous 3 years by Madsen and Associates, a PCAOB registered accounting firm   http://www.pcaob.org

http://www.pinksheets.com/pink/quote/quote.jsp?symbol=siaf

Most Recent Press Release

Sino Agro Food, Inc. to Register With Securities and Exchange Commission and Seek Quotation on the OTCBB

Company SEC Attorney

Michael T. Williams Esq.

Williams Securities Law Firm: 2503 W. Gardner Ct.
Tampa, FL  33611

http://www.gopublicdirect.com/index.php

Company Officers

 

Transfer Agent

 

• Phone: 6012-2004963
• Fax: 86-20-22057863
• E-mail: info@siafchina.com, leesyk@gmail.com Sino Agro Food, Inc.
  

 

BioDelivery Sciences International, Inc.

Nasdaq: BDSI

 

BioDelivery Sciences International, Inc. operates as a specialty pharmaceutical company in the United States. Its patented drug delivery technologies include BEMA drug delivery technology and Bioral cochleate drug delivery technology. The company, using its drug delivery technologies, develops formulations of pharmaceuticals aimed principally at short term acute conditions occurring in patients, primarily in the areas of pain and fungal infections. Its lead product is ONSOLIS, a treatment for pain in opioid tolerant patients with cancer. BioDelivery Sciences licensed the commercialization and distribution rights for ONSOLIS to Meda AB. The company’s products/formulations also include BEMA Buprenorphine, which is under preparation for phase 2 for moderate to severe and acute pain. Its lead Bioral formulation is an encochleated version of Amphotericin B, an anti-fungal treatment for systemic fungal infections. The company also has a Bioral formulation, which is in initial in vitro studies for the intranasal administration of Amphotericin B to treat chronic rhinosinusitis. BioDelivery Sciences has a research collaboration and licensing agreement with the Drugs for Neglected Diseases initiative (DNDi) to develop Bioral Amphotericin B for the treatment of neglected diseases, such as leishmaniasis and Chagas disease. The company was founded in 1997 and is based in Raleigh, North Carolina.

BDSI® Technology Platforms

New advances in drug delivery technologies are allowing many existing products to be administered with improved effectiveness, safety and/or ease of administration. Drug delivery technologies are also facilitating the advancement of many new drugs which face challenges with their current formulations.

BioDelivery Sciences' strategy is to utilize patented and proprietary drug delivery technologies to create products and formulations that meet important patient and healthcare provider needs. Presently, these opportunities will be primarily centered on the BEMA® and Bioral® technologies.

Bioral® is a novel drug delivery system, based upon cochleate technology. Bioral® encapsulates and protects a drug without chemically bonding to it and may facilitate oral dosing of drugs that typically need to be given by intravenous administration. Alternating layers of lipids spiral around a drug molecule, encapsulating it and potentially protecting it from degradation by acid or digestive enzymes in the stomach. The Bioral® technology is being evaluated as a new means of overcoming the poor oral absorption of drugs, such as the antifungal drug Amphotericin B and in programs involving siRNAs. Several pre-clinical studies have demonstrated the potential value of agents delivered using the Bioral® technology.1, 2, 3

The Bioral® drug delivery technology was developed in collaboration with the University of Albany and the University of New Jersey Medical and Dental School, each of which has granted BDSI® exclusive worldwide licenses under applicable patents. Collaboration with the National Institutes of Health has supported, in part, the Bioral® preclinical program, and a collaboration with the Walter Reed Army Institute of Research is currently exploring the use of Bioral® technology in difficult to treat parasitic infections.

 

 

 

 

---